Skip to main content
. 2021 Jan 14;13:379–392. doi: 10.2147/CMAR.S287676

Figure 1.

Figure 1

UBA6-AS1 plays an oncogenic role in GBM. (A) UBA6-AS1 expression in GBM was analyzed using TCGA database. (B) RT-qPCR analysis was conducted to detect UBA6-AS1 expression in 49 GBM tissues and 13 normal brain tissue samples. (C, D) TCGA database was employed to determine the association between UBA6-AS1 expression and overall survival or disease-free survival in GBM. (E) The expression level of UBA6-AS1 in a panel of GBM cell lines (A172, U251, U138 and T98) was measured by RT-qPCR, with a normal human astrocyte cell line NHA as the control. (F) Transfection efficiency of si-UBA6-AS1#1, si-UBA6-AS1#2, and si-UBA6-AS1#3 in U251 and T98 cells was evaluated by RT-qPCR analysis. (G) RT-qPCR was conducted to measure UBA6 expression in U251 and T98 cells after si-UBA6-AS1 or si-NC transfection. (H) U251 and T98 cells with UBA6-AS1 silencing were subjected to Cell Counting Kit-8 assay to evaluate cell proliferation. (I) The effect of si-UBA6-AS1 on U251 and T98 cell apoptosis was assessed by flow cytometric analysis. (J, K) Transwell migration and invasion assays were used to determine the migration and invasion abilities of U251 and T98 cells following si-UBA6-AS1 or si-NC transfection. *P < 0.05 and **P < 0.01.

Abbreviations: GBM, glioblastoma; RT-qPCR, reverse transcription-quantitative PCR; TCGA, The Cancer Genome Atlas; UBA6-AS1, UBA6 antisense RNA 1; si-NC, negative control small interfering RNA; si-UBA6-AS1, small interfering RNA targeting UBA6-AS1.